Significance of genetic Polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia

2007-01-01
Ulusoy, Gulen
Adalı, Orhan
Tumer, Tugba Boyunegmez
Sahin, Gurses
Gozdasoglu, Sevgi
Arinc, Emel
Background/Aims: The molecular etiology of childhood acute lymphoblastic leukemia (ALL) is likely to involve interactions between environmental factors and genetic make up. Understanding these interactions between various predisposing genes for the risk of developing childhood leukemia is of considerable importance. CYP2E1 is a susceptible gene in this respect, especially for its capacity to bioactivate many procarcinogens including benzene and N-nitrosodimethylamine. The CYP2E1 gene possesses several polymorphisms in humans, and among them, CYP2E1*5B and *6 have been shown to be associated with increased risks of several chemical-induced diseases. There are limited and contradictory data on the association between the CYP2E1*5B variant allele and childhood ALL, and none on such associations of CYP2E1*6 and *7B variant alleles. The aim of this study was to investigate the possible association of CYP2E1*5B, *6 and *7B alleles, alone or in combination, with the risk of incidence of childhood ALL in a Turkish population. Methods: The genotypes for both polymorphisms were determined by polymerase chain reaction/restriction fragment length polymorphism techniques on 207 healthy controls and 168 patients. Results: Neither locus was associated with the occurrence of childhood ALL. On the other hand, when both CYP2E1*5B and *6 alleles were considered together, the risk of childhood ALL increased significantly (2.9-fold; OR = 2.9, 95% CI 1.0-8.5; p <0.05). Moreover, the presence of at least 2 variant alleles of any combination increased the risk significantly 3.9 times, suggesting a combined effect (OR = 3.9, 95% CI 1.4-11.0). Conclusion: Individuals carrying combinations of CYP2E1*5B, *6 and *7B variants together are likely associated with the risk of developing childhood ALL. Copyright (c) 2007 S. Karger AG, Basel.
ONCOLOGY

Suggestions

Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway
Canli, Secil Demirkol; Seza, Esin Gulce; Sheraj, Ilir; Gomceli, Ismail; Turhan, Nesrin; Carberry, Steven; Prehn, Jochen H. M.; GÜRE, ALİ OSMAY; Banerjee, Sreeparna (Oxford University Press (OUP), 2020-09-01)
AKR1B1 and AKR1B10, members of the aldo-keto reductase family of enzymes that participate in the polyol pathway of aldehyde metabolism, are aberrantly expressed in colon cancer. We previously showed that high expression of AKR1B1 (AKR1B1(HIGH)) was associated with enhanced motility, inflammation and poor clinical outcome in colon cancer patients. Using publicly available datasets and ex vivo gene expression analysis (n = 51, Ankara cohort), we have validated our previous in silico finding that AKR1B1(HIGH) ...
Serum Glycan Signatures of Gastric Cancer
Özcan Kabasakal, Süreyya; Ruhaak, L. Renee; Torres, Javier; Cooke, Cara L.; An, Hyun Joo; Hua, Serenus; Williams, Cynthia C.; Dimapasoc, Lauren M.; Kim, Jae Han; Camorlinga-Ponce, Margarita; Rocke, David; Lebrilla, Carlito B.; Solnick, Jay V. (American Association for Cancer Research (AACR), 2014-02-01)
Glycomics, a comprehensive study of glycans expressed in biologic systems, is emerging as a simple yet highly sensitive diagnostic tool for disease onset and progression. This study aimed to use glycomics to investigate glycan markers that would differentiate patients with gastric cancer from those with nonatrophic gastritis. Patients with duodenal ulcer were also included because they are thought to represent a biologically different response to infection with Helicobacter pylori, a bacterial infection tha...
Monoclonal antibodies for targeted therapy in colorectal cancer.
Banerjee, Sreeparna (Informa UK Limited, 2010-04-15)
Traditional therapeutic regimens of solid tumors such as chemotherapy and radiotherapy often do not distinguish between malignant and normal tissues, resulting in considerable side-effects. Monoclonal antibodies (mAbs), targeted against antigens dysregulated in cancers, have therefore generated great interest in both clinical and research settings. The antibodies are either chimeric or human(ized) and can bind to and inhibit target proteins overexpressed in both solid tumors and hematological malignancies. ...
GST isoenzymes in matched normal and neoplastic breast tissue
OĞUZTÜZÜN, SERPİL; Abu-Hijleh, A.; ÇOBAN, TÜLAY; Bulbul, D.; KILIÇ, MURAT; İŞCAN, Mümtaz; İşcan, Mesude (AEPress, s.r.o., 2011-01-01)
The potential to metabolize endogenous and exogenous substances may influence breast cancer development and tumor growth. Therefore we investigated GST activity and the protein expression of glutathione S-transferases (GSTs) isoenzymes known to be involved in the metabolism of endogenous and exogenous carcinogens in breast cancer tissue to obtain new information on their possible role in tumor progression.
Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets
Duzkale, Neslihan; EYERCİ, NİLNUR; Oksuzoglu, Berna; Teker, Taner; Kandemir, Olcay (Elsevier BV, 2020-04-01)
BRCA1/2 genes with high-penetrance are tumor suppressor and tumor susceptibility genes that play important roles in the homologous recombination mechanism in DNA repair and increase breast cancer risk. Variants in BRCA1 or BRCA2 are the main causes of familial and early-onset breast cancer. This study investigated pathogenic variant belonging to the BRCA2 gene splice region in monozygotic triplets. A 44-year-old woman was diagnosed with breast cancer when she was 32 years old. Her monozygotic sister had a h...
Citation Formats
G. Ulusoy, O. Adalı, T. B. Tumer, G. Sahin, S. Gozdasoglu, and E. Arinc, “Significance of genetic Polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia,” ONCOLOGY, pp. 125–131, 2007, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/34980.